CoChat
Sign Up
Cited by 31

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

APOE and LRPAP1 gene polymorphism and risk of Parkinson’s disease

Singh, Neeraj Kumar, Banerjee, Basu Dev, Bala, Kiran, Mitrabasu, Dung Dung, Aldrin Anthony, Chhillar, Neelam·2014·Neurological Sciences
DOI 10.1007/s10072-014-1651-6
Open this paper in CoChat — free account

Abstract

Epidemiologic findings suggest that lipids and alteration in lipid metabolizing protein/gene may contribute to the development of neurodegenerative disorders. The aim of the current study was to determine the serum lipid levels and genetic variation in two lipid metabolizing genes, low-density lipoprotein receptor-related protein-associated protein (LRPAP1) and apolipoprotein E (APOE) gene in Parkinson's disease (PD). Based on well-defined inclusion and exclusion criteria, this study included 70 patients with PD and 100 age-matched controls. LRPAP1 and APOE gene polymorphism were analyzed by polymerase chain reaction and restriction fragment length polymorphism, respectively. Fasting serum lipid levels were determined using an autoanalyser. The logistic regression analysis showed that high levels of serum cholesterol [odds ratio (OR) = 1.101, 95 % confidence interval (CI95%) = 1.067-1.135], LRPAP1 I allelic variant alone (OR = 2.766, CI95% = 1.137-6.752) and in combination with APOE ε4 allelic variant (OR = 4.187, CI95% = 1.621-10.82) were significantly associated with increase in PD risk. Apart from that, the high levels of LDL cholesterol appears to have a protective role (OR = 0.931, CI95% = 0.897-0.966) against PD. The LRPAP1 I allelic variant may be considered a candidate gene for PD, predominantly in patients having the APOE ε4 allelic variant.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10072-014-1651-6

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. Perl DP, Olanow CW, Calne D (1998) Alzheimer’s disease and Parkinson’s disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 44:S19–S31 · DOI
  2. Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 52:695–701 · DOI
  3. Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348:1356–1364 · DOI · Paper page
  4. Singh NK, Chhillar N, Banerjee BD, Bala K, Mukherjee AK, Mustafa MD, Mitrabasu (2012) Gene–environment interaction in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 27:496–503 · DOI
  5. Tang G, Xie H, Xu L, Hao Y, Lin D, Ren D (2002) Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease. Am J Med Genet 114:446–449 · DOI
  6. Huang X, Chen PC, Poole C (2004) APOE-[varepsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62:2198–2202 · DOI
  7. Blázquez L, Otaegui D, Sáenz A, Paisán-Ruiz C, Emparanza JI, Ruiz-Martinez J, Moreno F, Martí-Massó JF, López de Munain A (2006) Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson’s disease. Neurosci Lett 406:235–239 · DOI
  8. Ezquerra M, Campdelacreu J, Gaig C, Compta Y, Muñoz E, Martí MJ, Valldeoriola F, Tolosa E (2008) Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease. Neurosci Lett 448:20–23 · DOI
  9. Gao J, Huang X, Park Y, Liu R, Hollenbeck A, Schatzkin A, Mailman RB, Chen H (2011) Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging 32:2106.e1–2106.e6 · DOI
  10. Pulkes T, Papsing C, Mahasirimongkol S, Busabaratana M, Kulkantrakorn K, Tiamkao S (2011) Association between apolipoprotein E genotypes and Parkinson’s disease. J Clin Neurosci 18:1333–1335 · DOI
  11. Alvim RO, Freitas SR, Ferreira NE, Santos PC, Cunha RS, Mill JG, Krieger JE, Pereira AC (2010) APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. Lipids Health Dis 9:128 · DOI
  12. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C (2007) Lower low density lipid cholesterol levels are associated with Parkinson’s disease. Mov Disord 22:377–381 · DOI
  13. Willnow TE, Armstrong SA, Hammer RE, Herz J (1995) Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci USA 92:4537–4541 · DOI · Paper page
  14. Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E (2010) Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 221:267–274 · DOI
  15. Dixit M, Choudhuri G, Keshri LJ, Mittal B (2006) Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease. J Gastroenterol Hepatol 21:847–849 · DOI
  16. Dixit M, Choudhuri G, Mittal B (2006) Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: a case-control study. Hepatol Res 36:61–69 · DOI
  17. Sánchez L, Alvarez V, González P, González I, Alvarez R, Coto E (2001) Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. Am J Med Genet 105:76–78 · DOI
  18. Schutte DL, Maas M, Buckwalter KC (2003) A LRPAP1 intronic insertion/deletion polymorphism and phenotypic variability in Alzheimer disease. Res Theory Nurs Pract 17:301–319 · DOI
  19. Pandey P, Pradhan S, Mittal B (2008) LRP-associated protein gene (LRPAP1) and susceptibility to degenerative dementia. Genes Brain Behav 7:943–950 · DOI · Paper page
  20. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, Van Den Eeden SK, Gorell J (2007) Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64:990–997 · DOI
  21. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A (2010) Smoking duration, intensity, and risk of Parkinson disease. Neurology 74:878–884 · DOI
  22. E O’Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A (2009) Smoking and Parkinson’s disease: using parental smoking as a proxy to explore causality. Am J Epidemiol 169:678–682 · DOI
  23. D Hong DP, Fink AL, Uversky VN (2009) Smoking and Parkinson’s disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta 1794:282–290 · DOI
  24. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL (2005) Alphasynuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson’s disease. Brain 128:2654–2664 · DOI
  25. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J (2008) Total cholesterol and the risk of Parkinson disease. Neurology 70:1972–1979 · DOI
  26. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J (2007) Association of apolipoprotein E genotype with lipid levels and coronary risk. JAMA 298:1300–1311 · DOI · Paper page
  27. Grönroos P, Raitakari OT, Kähönen M, Hutri-Kähönen N, Marniemi J, Viikari J, Lehtimäki T (2007) Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study. Clin Chem Lab Med 45:592–598 · DOI
  28. Addante F, Sancarlo D, Copetti M, Scarcelli C, Longo MG, Niro V, Paroni G, Pellegrini F, Fontana L, Pilotto A (2011) Effect of obesity, serum lipoproteins, and apolipoprotein E genotypes on mortality in hospitalized elderly patients. Rejuvenation Res 14:111–118 · DOI
  29. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW (2008) Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 23:1013–1018 · DOI · Paper page
  30. Tikhonoff V, Casiglia E, Mazza A, Scarpa R, Thijs L, Pessina AC, Staessen JA (2005) Low-density lipoprotein cholesterol and mortality in older people. J Am Geriatr Soc 53:2159–2164 · DOI
  31. Colpo A (2005) LDL Cholesterol: bad cholesterol or bad science? J Am Physicians Surg 10(3):83–89

Cited by

Sorted by citations

Metadata

Authors
Singh, N. K., Banerjee, B. D., Bala, K., Mitrabasu, Dung Dung, A. A., & Chhillar, N.
Venue
Neurological Sciences
Publisher
Springer Science and Business Media LLC
Published
2014-02-07
Volume
35
Issue
7
Pages
1075-1081
ISSN
  • 1590-1874
  • 1590-3478
DOI
10.1007/s10072-014-1651-6
Cited by
31
References
4
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review